Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2764 - The preventive role of intravenous L-alanyl L-Glutamine in reducing the incidence of oral mucositis in head and neck cancer patients receiving radiotherapy with or without chemotherapy


10 Sep 2017


Poster display session


Supportive Care and Symptom Management;  Head and Neck Cancers


Amany Elfeky


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


A.M. Elfeky, N. Sabry, A. Barakat

Author affiliations

  • Clinical Oncology And Nuclear Medicine, Tanta University Hospital, 31511 - Tanta/EG


Abstract 2764


The current prospective comparative phase 2 study aimed to assess the role of intravenous L-alanyl L-Glutamine in reducing the rate of oral mucositis for squamous head and neck cancer patients receiving radiotherapy with or without concurrent chemotherapy.


From September 2014 to Septemper 2016, 100 head and neck cancer patients were treated with radiotherapy or combined chemo-radiation at the Clinical Oncology Department, Tanta University Hospitals. Patients were randomized in 1:1 ratio into Group A (n = 50 patients) treated by radiotherapy or concurrent chemo-radiotherapy and Group B (n = 50 patients) to receive same treatment in addition to intravenous Glutamine. The investigational drug was infused daily at dose of 0.3-0.4 g/kg diluted in NS and administered at rate of 0.1g/Kg/hr. All patients received total dose of 65-70 Gy using Linac 6MV photon beam supplemented with electron beam when needed. For concurrent chemotherapy, Cisplatin (40mg/m2) was administered weekly.


Mucositis was assessed by WHO grading system. A significantly higher incidence of mucositis was reported in 45% of Group A patients compared with patients in group B who received glutamine 10% P 


Intravenous L-alanyl L-Glutamine may be an effective measure to lower incidence or prevention of oral mucositis in head and neck cancer patients treated by radiotherapy or combined chemo-radiation.

Clinical trial identification

Legal entity responsible for the study

Tanta University Hospital




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.